back to Australia directory
australia clinical guidance

Finerenone for chronic kidney disease in type 2 diabetes: pathway: source-status boundary

An Australian source-status record for finerenone for chronic kidney disease in type 2 diabetes: pathway. The attached documents do not support a complete claim-level clinical pathway, so this page makes no condition-specific diagnostic, treatment, monitoring or referral recommendation.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. This is a source-status boundary, not a clinical pathway. Verify an exact current Australian condition-specific source and the applicable state, territory or specialist-service pathway.

Scope

The attached source set (KHA CKD handbook, TGA product information, PBS listings) was audited for medicine specific registration product information and subsidy. It does not provide complete claim-level coverage for that pathway. This page therefore records the evidence boundary only and must not be treated as a clinical protocol or as evidence of medicine registration, subsidy or local service eligibility.
sources for this section:KHA CKD handbookTGA product informationPBS listings

The Bottom Line

  • No Australian diagnostic, treatment, medicine, monitoring, referral or subsidy recommendation for Finerenone for chronic kidney disease in type 2 diabetes: pathway is made on this page.
  • The attached source set is limited to KHA CKD handbook, TGA product information, PBS listings; its presence does not extend any source beyond its stated population, purpose or jurisdiction.
  • No threshold, dose, contraindication, test sequence, treatment order or referral timeframe should be inferred from this source-status record.
  • Use an exact current condition-specific source and the applicable state, territory, specialist-service and formulary pathway before making a clinical decision.
sources for this section:KHA CKD handbookTGA product informationPBS listings

How to find an applicable pathway

1
For a medicine decision, retrieve the exact active ARTG entry, current Australian approved product information and exact PBS item or restriction; a generic search or landing page is not prescribing or subsidy evidence.
2
Confirm the source version, publication status, population, setting and jurisdiction at the point of use, then document the exact pathway applied.
3
Keep regulatory approval, PBS subsidy, local formulary approval and service eligibility as separate checks; one does not establish the others.
4
If no exact source covers the decision, seek appropriate senior or specialist advice rather than filling the gap from an overseas pathway or from this page.
sources for this section:KHA CKD handbookTGA product informationPBS listings

Safety limitation

  • This page does not define condition-specific red flags, emergency tests or acute treatment for Finerenone for chronic kidney disease in type 2 diabetes: pathway.
  • If a person is acutely unwell, deteriorating or at immediate risk, use the current local emergency or retrieval pathway and condition-specific senior advice.
sources for this section:KHA CKD handbookTGA product informationPBS listings

Implementation boundary

Source availability, referral pathways, public-health directions, medicine access and funded services vary by state, territory and health service.
sources for this section:KHA CKD handbookTGA product informationPBS listings

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:KHA CKD handbookTGA product informationPBS listings

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Kidney Health AustraliaChronic Kidney Disease Management in Primary Care5th edition, 2024 路 accessed 2026-08-20
    view source
  2. Therapeutic Goods AdministrationAustralian prescription medicine product informationCurrent ARTG and approved product information checked at point of clinical review 路 accessed 2026-08-20
    view source
  3. Australian Government Department of Health, Disability and AgeingPharmaceutical Benefits Scheme medicine listings and restrictionsCurrent PBS Schedule must be checked at point of prescribing 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.